Christopher D. Payne

Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel

John T. Brandt, Sandra Close, Stephen J. Iturria et al. · Journal of Thrombosis and Haemostasis · 2007 · 726 citations

Medicine, Genetics, Pharmacodynamic Response +6

A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation

John T. Brandt, Christopher D. Payne, Stephen D. Wiviott et al. · American Heart Journal · 2006 · 568 citations

Thrombopoiesis, Thrombosis, Clopidogrel Loading Doses +12

Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease

Tomas Jernberg, Christopher D. Payne, Kenneth J. Winters et al. · European Heart Journal · 2006 · 535 citations · Full text

Cytochrome P450 3A Inhibition by Ketoconazole Affects Prasugrel and Clopidogrel Pharmacokinetics and Pharmacodynamics Differently

Nazar Farid, Christopher D. Payne, D. S. Small et al. · Clinical Pharmacology & Therapeutics · 2007 · 321 citations

Effects of the Proton Pump Inhibitor Lansoprazole on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel

David S. Small, Nagy A. Farid, Christopher D. Payne et al. · The Journal of Clinical Pharmacology · 2008 · 315 citations

Thrombopoiesis, Molecular Pharmacology, Thrombosis +15